A new MRSA and Clostridium difficile treatment is being developed by a Scottish biopharmaceutical company.
Researchers at Glasgow-based MGB Biopharma have hailed the MGB BP-3 antibiotic as “extremely promising”.
They claim that the compound is more effective in killing and preventing C.diff bacterium than the commonly used vancomycin.
Presenting their findings at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy in Chicago, the team said clinical trials of MGB BP-3 are due to take place next year.
MGB Biopharma chief executive officer Dr Miroslav Ravic said: “We are very excited that MGB BP-3 shows such a promising response against this troublesome and difficult-to-treat infection.
“We are committed to developing a specific oral drug for the treatment of Clostridium difficile infections in addition to the progress we are making with an IV drug against MRSA.”